TNFSF10 and cancer: A Phase I clinical trial demonstrated depletion of PMN-MDSCs and early MDSCs in cancer patients following treatment with an agonist antibody to tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL-32) [95].